Hypercalcemia in malignancies: treatment with dichloromethylene diphosphonate (Cl2MDP)

Eleven hypercalcemic patients affected by various kinds of cancer were treated with dichloromethylene diphosphonate (Cl2MDP), 400 mg diluted in 500 ml of saline solution, i.v., during 3 h. Drug administration normalized plasma calcium levels in all treated patients, within 72 h for patients with lun...

Full description

Saved in:
Bibliographic Details
Published inTumori Vol. 71; no. 1; p. 51
Main Authors Conte, N, Di Virgilio, R, Roiter, I, Caberlotto, L
Format Journal Article
LanguageEnglish
Published United States 28.02.1985
Subjects
Adult
Aged
Bone Neoplasms - complications
Bone Neoplasms - metabolism
Bone Neoplasms - secondary
Calcium - metabolism
Clodronic Acid - therapeutic use
Diphosphonates - therapeutic use
Drug Evaluation
Female
Humans
Hydroxyproline - urine
Hypercalcemia - drug therapy
Hypercalcemia - metabolism
Male
Middle Aged
Neoplasms - complications
Neoplasms - metabolism
Time Factors
Online AccessGet more information

Cover

More Information
Summary:Eleven hypercalcemic patients affected by various kinds of cancer were treated with dichloromethylene diphosphonate (Cl2MDP), 400 mg diluted in 500 ml of saline solution, i.v., during 3 h. Drug administration normalized plasma calcium levels in all treated patients, within 72 h for patients with lung cancer; within a longer period for other kinds of cancer. Moreover, Cl2MDP also reduced calciuria in treated patients. The use of the drug was not followed by side effects and was also well tolerated in patients with kidney insufficiency.
ISSN:0300-8916
2038-2529
DOI:10.1177/030089168507100109